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Summary: Plasma haemoglobin was assayed with the non-carcinogenic reagent phenothiazine. This method
is sensitive and allows the measurement of plasma haemoglobin concentrations in the range 4—500 mg/1 with
a within-run CV of 2.1%, and a between-run CV of 4.3%. A spectrophotometric scanning method (x) based
on the determination of haemoglobin as haemiglobin cyanide using the Soret band at 419 nm correlated well
with the phenothiazine method (y): y = l.OTx + 15.8, r = 0.995, n = 31. It was found that the absorbances
in the phenothiazine method were markedly dependent on the concentration of phosphoric acid.
Introduction
The quantitative determination of plasma haemoglo-
bin is of clinical importance in haemolytic disorders,
which occur either in vivo (1, 2) or in vitro (3).
However, the carcinogenity of many commonly used
reagents is undesirable for routine laboratories. Ben-
zidine, 0-tolidine (4) and dicarboxidine (5), used in
previous studies, are all carcinogens. Of the suggested
alternative non-carcinogenic chromogens, tetrame-
thylbenzidine (6, 7) aminophenazone (8), and 2,2'-
azino-di-(3-ethylbenzthiazoline-6-sulphonic acid)
(ABTS) (9, 10) have proved suitable for the quanti-
tative determination of plasma haemoglobin. The re-
action of these materials with haemoglobin is based
on the peroxidase activity of the haemoprotein. Spec-
trophotometric scanning techniques do not require
carcinogenic reagents (11, 12, 13), but are only acces-
sible to those laboratories possessing scanning equip-
ment.
Recently, Ferencz & Bacso (14) developed a method
for the determination of haemoglobin in plasma or
serum using phenothiazines. This method is also based
on the peroxidase activity of haemoglobin, but the
main reason for recommending this reagent is its non-
carcinogenity. They also introduced the use of phos-
phoric acid to stabilize the coloured reaction end
product. We have evaluated a modification of the
method using chlorpromazine and found it suffi-
ciently rapid and sensitive to measure plasma hae-
moglobin concentrations of 4 — 500 mg/1.
Materials and Methods
Glacial acetic acid, phosphoric acid and Na2EDTA were from
E. Merck (Darmstadt, F. R. G.). Chlorpromazine (250 mg) (Ph.
Nord., Yliopiston Apteekki, Helsinki, Finland) was dissolved
in 100 ml of 5.4 mmol/1 Na2EDTA. This solution is stable for
one week at 4- 4 °C. Phosphoric acid was diluted to 5 mol/1
with distilled water. Hydrogen peroxide (Bang & Co., Helsinki,
Finland) solution was freshly prepared daily from 300g/kg
H2O2 by diluting 3 A ml of H2O2 in 100 ml of distilled water.
All reagent$ were of "pro analysis" quality. A 300 μΐ aliquot of
whole blood, whose haemoglobin concentration had previously
been determined by Coulter Counter® S-PLUS IV (Coulter
Electronics, Inc., Hialcah, U.S.A.) using the haemiglobin cy-
anide technique checked by Coulter quality control 4c, was
haemolyzed by diluting to 100 ml with water. This solution was
used as a haemoglobin standard and is stable at 20 °C for at
least 6 months. Patient plasma samples were collected using
either sodium heparin or potassium EDTA tubes (Venoject,
Terumo Corp., Tokyo, Japan) which are used routinely in our
laboratory.
To 20 μΐ of plasma or standard we added 0.5 ml of chlorprom-
azine solution, 1.4 ml acetic acid and 0.2 ml of 5 mol/1 H3PO4.
Reaction was started by adding 1.0 ml of H2O2. The final
concentrations of the reagents of the assay mixture were:
chlorpromazine 0.4 g/l,
acetic acid 7.9 mol/1,
H3PO4 0.32 mol/1 and
H2O2 0.09 mol/1,
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The absorbance was measured against a blank which had been
prepared using pooled haemoglobin-free plasma. The absorb-
ance readings at 528 nm (Zeiss PM 2 DL Spektrophotometer,
Zeiss, Oberkochen, F. R. G.) were recorded exactly eight min-
utes after the addition of the H2O2 solution.
The haemoglobin-free plasma used as a blank was checked by
measuring the absorbance of the reaction against the reaction
of the sample replaced by water. This blank absorbance reading
was not allowed to exceed 0.07.
The effects of bilirubin and ascorbic acid on the assay were
studied. Bilirubin (Fluka AG, Buchs, Switzerland) 100 mg, was
dissolved in 0.1 mol/1 NaOH and diluted to 20 ml with 50 g/1
of bovine albumin solution (Sigma, St. Louis, USA). Ascorbic
acid (Merck) 200 mg was dissolved in 100 ml of water. These
stock solutions were added to pooled plasma.
Results and Discussion
The linearity of the method was checked by making
a series of dilutions of the standard in water and
analysing as described. To confirm the standardisa-
tion of the method we used a haemoglobin control
from Merz + Dade AG (Duedingen, Switzerland,
haemoglobin concentration 110 g/1). The control was
diluted and used in the same way as the standard.
Figure 1 shows the results obtained using dilutions of
the standard and the control.
The within-run coefficient of variation (CV) was 2.1 %
(n = 10) using a patient sample containing 362 mg/1
haemoglobin. The between run CV was 4.3%
(n = 10, sample containing 251 mg/1 haemoglobin).
The analyses for determining the between run varia-
tion were performed during a seven-week period.
It was found that a final concentration of 0.4 g/1
chlorpromazine in the assay mixture was sufficient,
provided the chlorpromazine solution was freshly pre-
pared. Higher concentrations of chlorpromazine led
to absorbance readings that were too high for meas-
urement with the spectrophotometer at the plasma
haemoglobin level of 430 mg/1 and above. During
storage the chlorpromazine solution slightly looses its
capacity to be peroxidized by hydrogen peroxide, and
the intensity of the coloured end product as well as
the linearity of the method are decreased.
The concentration of phosphoric acid in the reaction
mixture was of critical importance. The absorbance
of the reaction end product was found to increase as
the concentration of the phosphate increased (fig. 2).
However, the absorbance maximum was reached later
in higher phosphate concentrations and the colour
was more unstable (fig. 2). Ferencz & Bacso (14) used
the final concentration of 0.16 mol/1 H3PO4 in the
assay mixture to stabilize the colour of the end prod-
uct. However we found that 0.16 mol/1 instead of 0.32
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Fig. 1. Linearity of absorbanee readings against haemoglobin
concentration;








Fig. 2. Effect of the concentration of H3PO4 on the colour
development in the reaction mixture (chlorpromazine
0.4 g/1, glacial acetic aeid 7.9 mol/1, H2O2 0.09 mol/1
and 20 μΐ of a sample with 380 mg/1 of haemoglobin);
(ooo) without H3PO4,
( ) 0.32 mol/i H3P04,
(ooo) 0.64 mol/1 H3PO4,
(-—) 0.95 mol/1 H3P04.
The absorbance readings were taken at a 30 seconds
interval.
reduction in the absorbance values, and the linearity
of the method decreased (fig. 3). A final concentration
of 0.32 mol/1 H3PO4 proved to be the optimal with
respect to absorbance and stability for plasma hae-
moglobin concentrations of 4—500 mg/1. Samples
with haemoglobin concentrations above 500 mg/1
werfe diluted 1:5 with 9 g/1 NaCL*
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Fig. 3. Effect of the concentration of H3PO4 in the reaction
mixture.
(o), (o) represent the absorbances against concentration
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Fig. 4. Comparison of results observed using the chlorproma-
zine and haemiglobin cyanide method, dotted line:
y = x.
Cf. text for details.
The detection limit of the assay was 4 mg/1 which
corresponds to an absorbance reading of 0.01 at 528
nm. The normal range for plasma haemoglobin is
usually given as 0 — 25 mg/1 (4, 7) or 0 — 50 mg/1
(8,10).
The chlorpromazine method described (y) was com-
pared with the spectrophotometric scanning method
(x) based on the determination of haemoglobin as
haemiglobin cyanide using the Soret band at 419 nm
(4). A linear regression equation for the two methods
was y = 1.07x + 15.8 (31 patient samples), with hae-
moglobin concentrations between 0 — 1148 mg/1
(r = 0.995, fig. 4). The chlofproinazitie method gave
slightly higher results (paired t-test p< 0.001).
Lipaemic samples may cause erroneously high results.
For turbid samples we prepared sample blanks: 20 μΐ
of the sample was first treated with 1 ml of H2O2 for
10 minutes, followed by addition of other reagents.
Previous studies have demonstrated that the antico-
agulants oxalate, citrate, EDTA and heparin have no
effect on the phenothiazine methods. Ascorbic acid
in high concentration does inhibit the colour devel-
opment of both the phenothiazine and the benzidine
method in plasma and in urine (14, 15). We tested the
effect of ascorbic acid and bilirubin on the chlor-
promazine method. Ascorbic acid was added to
plasma to give final concentrations of 32, 56, 111 and
222 μηιοΐ/ΐ; and bilirubin was added to plasma to give
concentrations of 40, 80, 160 and 388 μιηοΐ/ΐ with a
haemoglobin concentration of 636 mg/1. Analytical
recoveries of haemoglobin in these samples were
96% —100% for plasma spiked with ascorbic acid
and 102% —109% for plasma spiked with bilirubin.
We conclude that neither ascorbic acid nor bilirubin
at their physiological or elevated concentrations have
any marked effect on this method.
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